Krystal Biotech, based in Pittsburgh, focuses on developing genetic medicines for diseases with high unmet needs, employing 229 staff since its IPO in September 2017. Its products include VYJUVEK for DEB and others targeting cystic fibrosis and solid tumors.
Krystal Biotech (KRYS) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Krystal Biotech's actual EPS was $1.20, beating the estimate of $1.39 per share, resulting in a 16.13% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
